Rimantadine (Орвирем) is commonly used across conditions presenting with Influenza A virus infection, which is characterized by acute or disruptive episodes.

What Орвирем Treats: Main Uses and Benefits

The use of this medication is centered on the Influenza A virus infection, and is relevant for both prophylaxis (prevention) and treatment of symptomatic illness in acute episodes. It is applied in clinical settings that involve acute or unstable symptom patterns, such as during seasonal outbreaks or after potential exposure.

The medication is relevant for managing symptoms related to systemic imbalance, including high fever, generalized malaise, severe headache, and widespread muscle ache. The use of this medication provides support that helps ease the overall symptom burden. The medication may assist with easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods.

The medication is commonly used to help with prophylaxis and treatment of illness caused by the Influenza A virus.

“This medication is considered relevant for easing the acute, characteristic symptoms of the flu.”

---

Quick Fact: Relief for Systemic Discomfort

Area of Benefit	Relief Type	Symptom Examples
Symptom Cluster	Management	Fever, headache, muscle ache (myalgia)
Therapeutic Goal	Supportive Relief	Helps ease overall symptom burden and distress
Context	Acute Episodes	Relevant during phases of increased systemic discomfort

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility Profile for Orvirem (Rimantadine)

This section outlines the population eligibility and non-eligibility for Orvirem as defined by authoritative government regulatory bodies.

Exclusion Criteria	Populations & Conditions
Absolute Contraindication	Known hypersensitivity to rimantadine, amantadine, or other drugs of the adamantane class.
Absolute Contraindication	Severe renal impairment (Creatinine clearance < 10 mL/min) or severe hepatic impairment.
Absolute Contraindication	Thyrotoxicosis.
Absolute Contraindication	Pregnancy and lactation (breastfeeding).

Restricted or Conditional Use	Populations & Conditions
Requires Caution/Adjustment	Patients with a history of epilepsy or other seizure disorders.
Requires Caution/Adjustment	Patients with chronic cardiovascular diseases, including heart failure or arterial hypertension.
Requires Caution/Adjustment	Older adults and patients with mild-to-moderate renal or hepatic impairment; dose reduction is often required.

Age-Specific Eligibility: The drug is typically approved for prophylaxis in children (starting from one year of age in some jurisdictions) but is restricted for treatment to older groups, often adults (17 years and older) or requiring different formulations/dosing based on age.

Interactions with other medicines and products

Орвирем (rimantadine) has a specific profile of drug interactions that must be considered before concurrent use with other medications. The potential for interaction stems primarily from the need to prevent additive effects on the central nervous system (CNS) and to ensure the antiviral's efficacy is maintained.

Documented Interacting Categories and Substances

• Live Attenuated Vaccines: The antiviral activity of rimantadine may interfere with the replication of live attenuated influenza virus vaccines, potentially reducing their effectiveness. Official recommendations advise avoiding the administration of the live attenuated nasal influenza vaccine during rimantadine use and for at least 48 hours following the final dose.
• CNS Stimulants and Sympathomimetics: Combining rimantadine with other CNS stimulants or sympathomimetic drugs may increase the risk of CNS adverse effects, such as nervousness, insomnia, dizziness, and difficulty concentrating, due to pharmacodynamic synergy.
• Acetylcholinesterase Inhibitors and other CNS-Active Drugs: Caution is advised when rimantadine is co-administered with medications that have anticholinergic or other CNS-related effects, including atropine-like compounds and certain antipsychotics. This combination can potentially enhance CNS-related side effects.
• Cimetidine: Concurrent use of cimetidine, a histamine H2 receptor antagonist, has been shown to decrease the clearance of rimantadine, leading to increased plasma concentrations and a higher risk of toxicity. Monitoring is necessary when these drugs are used together.
• Acetylsalicylic Acid (Aspirin) and Paracetamol: The co-administration of high doses of aspirin or paracetamol may reduce the plasma concentration of rimantadine, possibly lowering its therapeutic effectiveness. This interaction is generally considered minor but relevant in clinical practice.

Patients should inform their healthcare provider of all prescribed and over-the-counter medicines, vitamins, and herbal supplements they are currently taking to properly manage and monitor any potential drug-drug interactions.

Targeted Blockade of the M2 Proton Channel

Орвирем, containing Rimantadine, exerts its mechanism of action by targeting the Influenza A M2 protein, a crucial viroporin that functions as a pH-activated proton channel within the viral envelope. The drug acts as a non-competitive inhibitor by physically binding within the channel pore. This interaction occludes the channel, which prevents the necessary flow of H^+ ions into the viral core.

Arresting the Viral Uncoating Cascade

The inhibition of proton flux disrupts the essential viral endosomal acidification pathway. The resulting failure to acidify the core prevents the necessary dissociation of the M1 matrix protein from the viral genetic material (vRNP). This arrests the process of viral uncoating, thereby halting the release of the viral RNA into the host cytoplasm. This cascade results in the cessation of new virion production and a reduction in the concentration of new functional virions at the cellular level.

Mechanism Limitations

The mechanism is functionally constrained by the structural integrity of the M2 protein. Strains carrying M2 resistance mutations (e.g., S31N) prevent drug binding, thereby abolishing the blockade of the M2 channel and limiting the mechanism’s scope.

How to Use Орвирем (Rimantadine): Official Administration Guidelines

Rimantadine is administered according to standardized regimens detailed in prescribing information for the prophylaxis and early treatment of Influenza A. This section outlines the methods, doses, frequency, and duration of use.

---

Administration Route and Forms

Орвирем is approved solely for oral administration and is available in both 100 mg tablets and a syrup or oral solution (50 mg/5 mL). The tablets or solution may be taken with food or milk to help mitigate gastrointestinal upset.

Standard Dosing and Duration

The standard recommended dose for adults (age 17 and older) for both treatment and prophylaxis is 100 mg twice a day (b.i.d.). For the treatment of acute infection, therapy is to be continued for 7 days and must be initiated within 48 hours of the onset of symptoms. Prophylactic use typically continues for the duration of exposure or outbreak, up to a period of 6 weeks.

Indication	Standard Adult Dose (Age ≥ 17)	Treatment Duration
Treatment of Influenza A	100 mg times 2 times daily	7 days
Prophylaxis of Influenza A	100 mg times 2 times daily	Up to 6 weeks

Population-Specific Adjustments

Dose modifications are required for certain patient groups to prevent drug accumulation:

• Severe Impairment: Patients with severe hepatic dysfunction or severe renal failure (Creatinine Clearance ≤ 10 mL/min) require a reduced dose of 100 mg once a day.
• Older Adults: The dose is reduced to 100 mg once a day for elderly nursing home patients.
• Pediatric Dosing: Children 1 to 9 years of age receive a weight-based dose of 5 mg/kg once a day, not to exceed 150 mg daily.

Research evidence / Overview of studies for Орвирем (Rimantadine)

---

Evidence for use in Preventing and Treating Influenza A

Research exploring Rimantadine's activity was primarily conducted through older, placebo-controlled, double-blind Randomized Controlled Trials (RCTs). These studies examined the medicine's use for both preventing (prophylaxis) and managing the acute phase of uncomplicated Influenza A illness in otherwise healthy adults and children.

The measured outcomes included the incidence of confirmed Influenza A infection in prevention studies and the duration of acute systemic symptoms (such as fever and malaise) in treatment studies. Findings from older trials reported that the period of symptom activity was numerically different in the group receiving the medication compared to control groups, typically by about one to two days in those who started treatment early.

Evidence Consistency, Resistance, and Limitations

A critical finding documented in the scientific literature is the frequent recovery of drug-resistant virus strains during both prophylactic use and acute treatment. This research highlights the significant limitation that widespread resistance to this class of medicine now exists in contemporary circulating Influenza A viruses. Consequently, the applicability of the older research findings to today's flu strains remains highly uncertain.

Research Gaps and Uncertainty

Current data for certain high-risk groups, such as the elderly or individuals with chronic health conditions, remain insufficient. Furthermore, most trials had limited follow-up durations, meaning long-term health outcomes beyond the immediate illness or season are not fully established. Studies exploring comparisons between Rimantadine and other medicines are also lacking. Much is still uncertain regarding the data on today's circulating flu viruses.

Common questions about Орвирем (FAQ)

Q: What should I do if I miss a dose of Orvirem?

If a dose is missed, official product information recommends taking it as soon as you remember. However, if it is nearly time for your next scheduled dose, the label recommends skipping the missed dose and resuming the regular schedule. To maintain the correct therapeutic concentration, it is advised not to double the dose to make up for a missed one.

Q: How can I safely get rid of expired Rimantadine at home?

Official disposal guidelines recommend utilizing an authorized drug take-back program whenever possible. If such a program is not available, the medicine may be prepared for household trash disposal. This involves mixing the expired medication with an undesirable substance, like dirt, used coffee grounds, or cat litter, and sealing the mixture in a container, such as a plastic bag, before disposal. Official guidance strongly advises against flushing the medicine down a toilet or pouring it down a drain.

Q: Is Orvirem safe to use during pregnancy?

No, official prescribing information lists the use of rimantadine as an absolute contraindication for both pregnancy and breastfeeding (lactation). Official product information notes that animal studies suggest a potential risk, and adequate well-controlled studies confirming its safety for pregnant women are not available.

Q: What should I do if I accidentally take too much Orvirem (overdose)?

While specific overdose data for rimantadine is limited, reports involving similar drugs have documented reactions such as hallucinations, agitation, and cardiac rhythm problems. Official guidance emphasizes the need to seek emergency medical attention immediately if an overdose is suspected.

Q: Does Orvirem treat the 'stomach flu' (gastroenteritis)?

Official indications confirm that Orvirem (rimantadine) is used solely for the prophylaxis and early treatment of illness caused by the Influenza A virus. It does not have activity against other types of flu viruses, colds, or the viruses that cause gastroenteritis, which is commonly referred to as 'stomach flu.'

Q: Can I drink alcohol while taking Orvirem?

Official safety information notes that rimantadine can cause central nervous system (CNS) side effects, including dizziness, confusion, or insomnia. Official labeling suggests alcohol use may increase the likelihood or severity of these adverse reactions.

Q: Is Orvirem effective against Influenza B?

According to the official product information and clinical microbiology data, rimantadine is a targeted antiviral agent with demonstrated inhibitory activity against only the Influenza A virus. It is considered to have little to no therapeutic effect against the Influenza B virus.

How to Store and Dispose of Orvirem (Rimantadine)

Official regulatory documents define strict conditions for the storage and disposal of Orvirem tablets and oral solution.

Storage Requirements

• Temperature: The medicine must be stored at Controlled Room Temperature, which is specified as 20 C to 25 C (68 F to 77 F).
• Protection: The container must be kept tightly closed to protect the contents from moisture and environmental exposure.
• Child-Safety: The product must be stored strictly out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired medicine should follow official guidance. The preferred method is to utilize an authorized drug take-back program. If a program is unavailable, the medicine must be prepared for household trash disposal by mixing it with an undesirable substance (e.g., dirt, coffee grounds) and placing it in a sealed container. The medicine is not to be flushed down a toilet or poured down a drain.